| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
The purpose of the present study was to evaluate multiple organ dysfunction and prognosis by multiple biomarkers and invasive hemodynamic methods in patients with chronic circulatory failure. We have reported plasma levels of cyclophilin A (CyPA) predicted cardiovascular prognosis in patients with coronary artery disease (CAD). We have also found that plasma CyPA as a useful biomarker for evaluation of the effects of balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. In the field of adult congenital heart disease (ACHD), we have reported (1) hepatitis C virus positivity adversely impacted cardiac function and long-term prognosis in patients undergoing heart surgery before 1992 and (2) ACHD patients with high MELD-XI (Model for End-Stage Liver Disease Excluding INR) score had poor cardiovascular outcomes, and (3) PR interval prolongation predicted cardiovascular prognosis in adults with repaired tetralogy of Fallot.
|
